论文部分内容阅读
高同型半胱氨酸血症(hypohomocysteinemia,Hhcy)通过多种机制诱发动脉粥样硬化(atherosclerosis,AS),成为卒中防治领域的研究热点。理论上B族维生素干预可以降低血浆同型半胱氨酸(homocysteinemia,Hcy)水平,进而有效防治卒中。中美卒中防治指南均推荐使用多种B族维生素干预Hhcy~([1-2])。但多个大型临床研究结果~([3-4])显示,B族维生素干预治疗并未降低卒中的发生及再发风险。现就Hhcy的发生机制、Hhcy与卒中发病风险、B族维生素干预治疗后Hcy水平及卒中风险的相关研究综述如下。
Hypocellular hyperhomocysteinemia (Hhcy) induces atherosclerosis (AS) through a variety of mechanisms and becomes a research hotspot in the field of stroke prevention and treatment. Theoretically B vitamins can reduce plasma homocysteinemia (Hcy) levels, and thus effective prevention and treatment of stroke. The guidelines for the prevention and treatment of stroke in both China and the United States recommend the use of a variety of B vitamins Intervention Hhcy ~ ([1-2]). However, the results of several large clinical trials (3-4) show that B vitamins intervention did not reduce the incidence of stroke and risk of recurrence. Now on the mechanism of Hhcy, Hhcy and stroke risk, B vitamin treatment intervention Hcy levels and stroke risk related studies are summarized below.